Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

The sale of remaining rights to Allogene ends acrimony between the two companies.

Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.

The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.

Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.

The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.